Soft Tissue Allografts Market to Grow at an Estimated CAGR of 7.5% During the Forecast Period 2022-2030

10 Nov 2022

Soft tissue allografts are predicted to grow 7.5% from 2023 to 2030. In 2021, the industry made $4.2 billion. Rising accident injuries and ageing populations are driving the market growth. According to the World Health Organization (WHO), there will be 1.4 billion people 60 and older by 2030. Technology has helped soft tissue allografts gain popularity. The ageing population, demand for soft tissue allografts in athletics, expansion in tissue banks, and increase in orthopaedic surgical procedures are driving the need for sterile tissue allografts. Most companies are preparing soft tissue allografts. Increased awareness should help the global market for soft tissue allografts. Internet connectivity and social media have helped improve patient education. Increased consumer understanding of products and procedures should benefit the worldwide soft tissue allografts market. Healthcare trends, the rise of sports, and the ageing population are expected to boost the market growth.

Athletes in modern athletics, field events, and other contact sports, such as American football, are needed to train hard. Overtraining causes muscle and bone weariness and damage. High-intensity workouts boost athletic performance, but overtraining doesn't. Accidents, impacts, incorrect training habits, lack of conditioning, inappropriate equipment, and inadequate warm-up and stretching can cause sports injuries. Young people are getting more injured by playing one sport year-round. The American Academy of Paediatrics estimates that 30 million U.S. children and teens participate in organised sports annually, resulting in more than 3.5 million injuries. One-third of children's injuries are sports-related.

Age increases the risk of soft tissue injury. Age makes people slower, less energetic, and weaker. This causes more injuries. Elderly people are most likely to die from falls. It's the leading reason older patients visit the ER. Disease or trauma causes tooth loss in the elderly. Dental implants have a long and complex history as tooth replacements. Dental implant designs, materials, and techniques have grown in recent years. As the market for dental implants and cosmetic dentistry grows, it's expected to rise. This is expected to boost the soft tissue allografts market.

Browse for report at : https://www.acutemarketreports.com/report/soft-tissue-allografts-market

Osteoarthritis causes discomfort and disability; hence the market is expected to rise due to its increasing prevalence. According to the UK's National Health Service in 2020, tennis elbow impacted 1% to 3% of the population, or 4 to 7 cases per 1,000 persons each year. Technological advances are boosting the soft tissue market. Today's firms aim to launch items that will expand the market, but customers' understanding and awareness of these products will also be important. Expanded internet connection and easier access to social media have increased the public's understanding. The soft tissue market will benefit from growing familiarity with goods and production methods.

More trauma victims The WHO estimates that 1.3 million individuals die prematurely in automobile accidents each year. 20 to 50 million people are handicapped by non-fatal injuries, and most can't work. Musculoskeletal disorders affect 1.71 billion persons worldwide. According to the World Bank, worldwide per capita income rose 4.8% in 2021, compared to 1.5% in 2019.

Dental Allograft, Tendon Allograft, Cartilage Allograft, Meniscus Allograft, and Other Allografts are market segments. In 2021, dental allograft dominated. After an extraction, a dental bone transplant is usually performed to maintain the edentulous area for an implant. After tooth extraction, ridge augmentation and socket preservation reduce bone loss and abnormalities. By using a bone transplant, ridge augmentation can restore lost height and width and prevent further bone loss. "Socket preservation" involves filling an extraction socket with bone or a bone substitute to promote the outcome of following dental procedures like implants, dentures, or bridges. When upper posterior teeth are extracted, the maxillary sinus floor may loosen and fall out, leaving little bone.

OCA transplantation is one alternative for patients missing cartilage or osteochondral tissue. One study, "Osteochondral Allograft Transplant for Focal Cartilage Defects of the Femoral Condyles: Clinically Significant Outcomes, Failures, and Survival at a Minimum 5-Year Follow-up," found that osteochondral transplant shows significant clinical improvement and durability at mid-to-long-term follow-up, with 5 and 10-year survival rates of 86.2% and 81.8%, respectively. The study found that OCA's increased efficacy will drive segmental growth.

Cartilage allografts are vital in orthopaedic surgeries like joint repair. Cartilage graft transplantation is used to treat chondral and osteochondral diseases, especially in the knee. These operations can enhance the quality of life and reduce symptoms for those with cartilage-related joint conditions. Osteochondral allograft (OCA) involves transplanting mature, living joint cartilage (known as "chondrocytes"). These cartilage cells can survive the transplant and support cartilage matrix formation indefinitely.

2021 hospitals dominate the market. Soft tissue allograft is used for shoulder repair, spinal fusion, knee and ankle joint reconstruction, meniscal replacement, cancer or damage rebuilding, dental ridge augmentation, and urological treatments. More than 200,000 anterior cruciate ligaments (ACL) repairs are performed each year, or 30 to 78 per 100,000 people. ACL restoration procedures have developed from open surgeries that limited postoperative weight-bearing and range of motion to arthroscopically aided single-incision approaches. Similarly, graft selection has shifted.

North America dominated soft tissue allografts in 2021. Due to its key players and high rate of technology adoption, this area is predicted to have the greatest CAGR from 2023 to 2030. The incidence of diabetic foot ulcers, advances in diabetes healthcare awareness campaigns, and an increase in surgical procedures are also growing the soft tissue allograft market in North America. New items are expected to drive regional market growth. The FDA approved an ACL implant in December 2020. This implant was created as an ACL reconstruction alternative. This device can rebuild the ACL utilising an allograft, autograft, or only sutures.

"Canadian Institute for Health Information 2020" found that the number of Canadians undergoing joint replacement surgery has grown over the past five years, with 138,000 surgeries annually. Canada performed 63,000 hip and 75,000 knee replacements in 2019–2020. The rising number of hip and knee replacements in Canada is expected to fuel the demand for soft tissue allografts. The growing burden of diseases creates a tremendous opportunity for market participants, who are focused on R&D to deliver innovative, trustworthy goods, boosting the market growth. Integra LifeSciences Holding Corporation released AmnioExcel Plus Placental Allograft Membrane in 2020 to accelerate soft tissue recovery. The company created this product. Due to these factors, the market is expected to rise rapidly in the coming year.

Soft tissue allografts are a competitive market with several worldwide competitors. Competitors include Abbvie Inc. (Allergan), Conmed Corporation, Becton Dickinson and Company, Smith & Nephew (Osiris Therapeutics Inc.), Integra LifeSciences Corporation, Stryker Corporation, Zimmer Biomet, Arthrex Inc., Direct Biologics. New product launches by these players are also boosting demand for these products. The worldwide soft tissue allografts market has many important players, which fragments it. The main players have expanded their product lines and made mergers and acquisitions.

View Other Reports